Skip to Main Content
Table 2—

Prospective studies of OHA for type 2 diabetic patients using electronic monitoring

ReferencenPopulationAge (years)MedicationsFollow-upHbA1cAdherence rateDose interval*
Mason et al. (26) 21 Clinic — Sulfonylurea 3 months >8% 74.5%  
Matsuyama et al. (27) 15 Intervention 84 ± 8 OHA 3 months 12.7 ± 1.9 85.1%  
 17 Control    12.1 ± 2.6 82.8%  
Paes et al. (28) 91 Community 69 OHA 6 months — 67.2 ± 30%  
      (40 o.d.) 79.1 ± 19% 77.7 ± 21% 
      (36 b.i.d.) 65.6 ± 30% 40.7 ± 28% 
      (15 t.i.d.) 38.1 ± 36% 5.3 ± 5% 
Rosen et al. (29) 77 Clinic 65 Metformin 4 weeks 7.9 ± 1.1 77.7 ± 18%  
Rosen et al. (30) 16 Intervention 63 ± 11 Metformin 6 months  79.3 ± 13%  
 17 Control     60.7 ± 13%  
ReferencenPopulationAge (years)MedicationsFollow-upHbA1cAdherence rateDose interval*
Mason et al. (26) 21 Clinic — Sulfonylurea 3 months >8% 74.5%  
Matsuyama et al. (27) 15 Intervention 84 ± 8 OHA 3 months 12.7 ± 1.9 85.1%  
 17 Control    12.1 ± 2.6 82.8%  
Paes et al. (28) 91 Community 69 OHA 6 months — 67.2 ± 30%  
      (40 o.d.) 79.1 ± 19% 77.7 ± 21% 
      (36 b.i.d.) 65.6 ± 30% 40.7 ± 28% 
      (15 t.i.d.) 38.1 ± 36% 5.3 ± 5% 
Rosen et al. (29) 77 Clinic 65 Metformin 4 weeks 7.9 ± 1.1 77.7 ± 18%  
Rosen et al. (30) 16 Intervention 63 ± 11 Metformin 6 months  79.3 ± 13%  
 17 Control     60.7 ± 13%  
*

Dose interval = proportion of dose taken within the prescribed number of hours between doses (e.g., b.i.d. = 12 ± 6–h interval).

Close Modal

or Create an Account

Close Modal
Close Modal